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Abstract
Esters of phthalic acid (phthalates) are largely used in industrial plastics, medical devices, and pharmaceutical formulations.
They are easily released from plastics into the environment and can be found in measurable levels in human fluids.
Phthalates are agonists for peroxisome proliferator-activated receptors (PPARs), through which they regulate translocator
protein (TSPO; 18 kDa) transcription in a tissue-specific manner. TSPO is a drug- and cholesterol-binding protein involved in
mitochondrial respiration, steroid formation, and cell proliferation. TSPO has been shown to increase during differentiation
and decrease during maturation in mouse adipocytes. The purpose of this study was to establish the effect of mono-(2-
ethylhexyl) phthalate (MEHP) on the differentiation of human SW 872 preadipocyte cells, and examine the role of TSPO in
the process. After 4 days of treatment with 10 mM MEHP, we observed changes in the transcription of acetyl-CoA
carboxylase alpha, adenosine triphosphate citrate lyase, glucose transporters 1 and 4, and the S100 calcium binding protein
B, all of which are markers of preadipocyte differentiation. These observed gene expression changes coincided with a
decrease in cellular proliferation without affecting cellular triglyceride content. Taken together, these data suggest that
MEHP exerts a differentiating effect on human preadipocytes. Interestingly, MEHP was able to temporarily increase TSPO
mRNA levels through the PPAR-a and b/d pathways. These results suggest that TSPO can be considered an important player
in the differentiation process itself, or alternatively a factor whose presence is essential for adipocyte development.
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Introduction
Phthalates are esters of phthalic acid largely used in industrial
plastics to increase the flexibility of polymers, household items, and
medical devices, and in pharmaceutical formulations such as
stabilizers, lubricants, and emulsifying agents [1]. Due to a lack of
covalent bonds between plastics and phthalates, phthalates are
easily released from plastics into the environment [2,3]. According
to the United States Environmental Protection Agency, the United
States Agency for Toxic Substances and Disease Registry, and the
Medical Devices Bureau of Health (Canada), the largest exposure
of the general population to di-(2-ethylhexyl) phthalate (DEHP)
occurs via food, followed by indoor air contamination [4,5]. The
range of exposure in the general population (excluding medical
and occupational sources) is estimated at 3–30 mg/kg body
weight/day, and infants and toddlers are the most exposed (18.9
and 25.8 mg/kg body weight/day, respectively) [4–7]. Phthalates
are rapidly metabolized and excreted in urine and feces [8], but
are found in measurable levels in blood, semen, and breast milk
[9–11].
Mono-(2-ethylhexyl) phthalate (MEHP), the most toxic metab-
olite of DEHP, is a well-known ligand for the peroxisome
proliferator-activated receptor (PPAR) family, as are all other
phthalates. PPARs are nuclear receptors that act as transcription
factors of genes involved in lipid and glucose metabolism [12–14].
At present 3 isoforms have been identified, named PPAR-a, b/d,
and c. The expression of PPAR-a was traditionally associated with
the liver [15], where it is responsible for lipid catabolism [13,14].
However, it was recently demonstrated that PPAR-a can
upregulate b-oxidation and decrease glucose utilization in human
white adipocytes [16]. PPAR-b/d is ubiquitous and has been
observed to play a role in the regulation of energy homeostasis in
skeletal muscle [17], and in keratinocyte proliferation and
differentiation during wound healing [18]. PPAR-c is the major
isoform found in adipose tissue, but it is also expressed at high
levels in the spleen and digestive tract [15]. Its main functions in
the adipose tissue are the storage of lipids [14,19] and the
regulation of adipocyte differentiation [14,20,21]. More general-
ized effects of PPAR-c have also been observed; its agonists
(thiazolidinediones) have been shown to lower blood pressure [22]
and exert an antitumor effect in many cell lines and organs [23].
In a previous study, we demonstrated that phthalates decrease
the levels of testicular translocator protein (TSPO; 18 kDa)
mRNA and of circulating testosterone in mice through the action
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previously known as peripheral-type benzodiazepine receptor
(PBR) [25], is part of a multimeric protein complex that is located
in the outer mitochondrial membrane (OMM). TSPO is quite
ubiquitous, but it is expressed in high levels in steroidogenic
tissues, where it exerts its main function of cholesterol transport
into mitochondria, and supports steroid biosynthesis. Besides
cholesterol transport into mitochondria, TSPO is involved in
many cellular functions, such as mitochondrial respiration,
mitochondrial permeability transition pore opening, apoptosis,
and cell proliferation [25,26]. We have shown that protein kinase
C e (PKCe) affects TSPO expression through the mitogen-
activated protein kinase (MAPK) pathway [27]. In cell lines
expressing low endogenous levels of TSPO, stimulation by phorbol
12-myristate 13-acetate (PMA) has been demonstrated to cause an
increase in TSPO levels [28]. The expression of TSPO in 3T3-L1
preadipocyte cell lines, and the upregulation of TSPO mRNA
during adipogenesis, has been demonstrated [29]; however,
further information about the role of TSPO in adipose tissue is
lacking. TSPO was previously detected by a radioligand binding
assay in the interscapular brown adipose tissue [30] and in the
epididymal adipose tissue where its expression is increased in
response to acute stress [31].
The aim of the present study was to evaluate the effect of
MEHP on the differentiation of human preadipocytes from the
human liposarcoma-derived SW 872 cell line, and investigate the
relationship between the PPAR family and TSPO.
Methods
Cell Culture
Human liposarcoma SW 872 cells were purchased from
American Type Culture Collection (ATCC, Manassas, VA,
USA), cultured in 75-cm
2 flasks (Dow Corning Corp., Corning,
NY, USA) in a humidified atmosphere with 3.5% CO2 at 37uC, in
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12
(Invitrogen Canada Inc., Burlington, ON, Canada) supplemented
with 10% fetal bovine serum (Invitrogen Canada Inc.). SW 872
cells differentiate over time in culture without the use of any
differentiation media [32]. Indeed, SW 872 are preadipocytes
which stop proliferating when they reach 100% confluence. It is at
this point when they begin differentiating into adipocytes.
Quantification of mRNA levels by quantitative real time-
polymerase chain reaction (qRT-PCR)
SW 872 cells were plated onto 6-well plates (Dow Corning
Corp.) at the initial concentration of 7.5610
4 cells per well. After 1
day (60% confluence, D0), the cells were treated with 1, 10, and
50 mM of MEHP and 10, 50, and 100 nM of PMA (all purchased
from Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) for a
period of 4, 8, or 12 days.
Total RNA was extracted from cultured cells using RNeasy
Mini Kit (Qiagen Inc., Mississauga, ON, Canada) according to
manufacturer’s instructions. The RNA concentration was deter-
mined by measuring absorbance at 260 nm using the NanoDrop
ND-1000 (Thermo Scientific, Mississauga, ON, Canada). The
purity of RNA samples was determined by the A260/A280 (.2.0)
and the A260/A230 (2.0–2.2) values.
Samples were normalized to total RNA content and then
reverse transcribed using Transcriptor First Strand cDNA Syn-
thesis Kit (Roche Applied Science, Laval, QC, Canada) according
to manufacturer’s instructions. The resulting cDNA samples were
diluted with nuclease-free water and subjected to qRT-PCR using
the SYBR green dye technique on a Light Cycler system 480
(Roche Applied Science). Briefly, samples were pre-incubated at
95uC for 5 min followed by 45 cycles of denaturation at 95uC for
10 s, annealing at 61uC for 10 s and elongation at 72uC for 10 s.
Following PCR amplification, the identity of the amplification
product was verified by electrophoresis on a 2% agarose gel and
by melting curve analysis. The results reported for each RNA
product have been normalized to ribosomal protein S18 (RPS18)
mRNA to correct for differences in the amounts of the template
cDNA. Oligonucleotide sequences of sense and antisense primers
are shown in Table 1.
Triglyceride quantification assay
Triglyceride concentration was measured with a colorimetric
assay. Briefly, cells were seeded in 75-cm
2 flasks (Dow Corning
Corp.) and were maintained for 24 h to allow adherence. The
Table 1. Primers used for qRT-PCR analysis.
mRNA Forward primer 59-39 Reverse primer 59-39
ACACA CGGGAGAAGAGGGAATTGGACCCG TAGGCCAATGAGGATTCTCCAG
ACLY CGGACCGAAGTCACAATCTTTGTCCG GGTCTTCCCGACTTCTCCCATC
C/EBP-a CGGTCATTGTCACTGGTCAGC CGTTGGGTGGACAAGAACAGCAACG
GLUT1 CGGAACTTCGATGAGATCGCTTCCG AACAGCTCCTCGGGTGTCTTG
GLUT4 GGGCCTGCCAGAAAGAGTCTG CGATGCCAGCACTCCAGAAACATCG
PKCe CTGCCTTTGCCCAACACCTT CGGACGGTGAGAATGGCGAAGTCCG
PPAR-a TTCCTGCAAGAAATGGGAAACA CGGCTTCCAGAACTATCCTCGCCG
PPAR-b/d GGCAGCCTCAACATGGAGTG CGGGAACACCGTAGTGGAAGCCCG
PPAR-c ATGGAGTTCATGCTTGTGAAGGA CGGAGGCTTCAATCTGATTGTTCTCCG
RPS18 CGGGCATCCTCAGTGAGTTCTCCCG TCATGTGGTGTTGAGGAAAGCA
S100B CACGAGCACTCATGTTCAAAGAACTCGTG ATGGAGACGGCGAATGTGACT
TSPO GGTGGATCTCCTGCTGGTCA CGACCAATACGCAGTAGTTGAGTGTG
ACACA, Acetyl-CoA carboxylase alpha; ACLY, ATP citrate lyase; C/EBP-a, CCAAT/enhancer binding protein alpha; GLUT1, Glucose transporter 1; GLUT4, Glucose
transporter 4; PKCe, protein kinase C e; PPAR-a, peroxisome proliferator-activated receptor alpha; PPAR-b/d, peroxisome proliferator-activated receptor beta/delta;
PPAR-c, peroxisome proliferator-activated receptor gamma; RPS18, ribosomal protein S18; S100B, S100 calcium binding protein B; TSPO, translocator protein 18-kDa.
doi:10.1371/journal.pone.0028750.t001
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Aldrich Canada Ltd.) for 4 or 6 days; then samples containing
1610
7 cells each were homogenized in 1 ml 5% Triton-X100, and
slowly heated to 90uC in a water bath for 5 min. After a second
heating, samples were centrifuged and the supernatant was diluted
10-fold with distilled water. The Triglyceride Quantification assay
(Abcam, Cambridge, MA, USA) was performed according to the
manufacturer’s instructions and the reaction was quantified by
spectrophotometer at 595 nm using a VICTOR
TM X5 Multilabel
Plate Reader (PerkinElmer Inc., Waltham, MA, USA). The
triglyceride concentration (mM/10
7 cells) was calculated according
to the formula C=Ts/Sv; where C is the concentration, Ts is the
triglyceride amount from the standard triglyceride curve, and Sv is
the sample volume in the well.
Bromodeoxyuridine (BrdU) proliferation assay
Cell proliferation was evaluated using the BrdU assay (Roche
Applied Science), a colorimetric immunoassay based on the
incorporation of BrdU during DNA synthesis in proliferating cells.
Briefly, cells were seeded in 96-well plates (Dow Corning Corp.) at
the initial concentration of 2000 cells/well and were maintained
for 24 h to allow adherence. The culture medium was supple-
mented with 10 mM of MEHP (Sigma-Aldrich Canada Ltd.) for 3
days. Following this, BrdU solution was added to the well for 8 h,
then the medium was aspirated and cells were fixed with FixDenat
(provided with the assay) for 30 min at room temperature.
FixDenat was then removed and the samples were incubated for
90 min with anti-BrdU solution at room temperature. After
washing the wells, the amount of immune complex in each well
was quantified by spectrophotometric measurement at 490 nm
and 690 nm with VICTOR
TM X5 Multilabel Plate Reader
(PerkinElmer Inc.). Results were obtained by subtracting absorp-
tion at 690 nm from the absorption at 490 nm for each sample.
The subtracted absorbances were then normalized to control
values and expressed as percent of BrdU incorporation.
Transfection of small interfering RNA (siRNA)
Cells were plated onto 6-well plates (Dow Corning Corp.) at an
initial concentration of 7.5610
4 cells per well, and immediately
transfected with siRNA using Lipofectamine
TM 2000 (Invitrogen
Canada Inc.) according to manufacturer’s instructions. PKCe
(80 nM), PPAR-b/d (40 nM), PPAR-c (40 nM), and TSPO
(40 nM) siRNAs were all part of the ON-TARGETplus SMART-
pool range of siRNA products produced by Dharmacon Products,
Thermo Fisher Scientific (Lafayette, CO, USA). PPAR-a siRNA
(SilencerH validated siRNA, 40 nM) was purchased from Applied
Biosystems Canada (Streetsville, ON, Canada), and a scrambled
siRNA (ON-TARGETplus Non-Targeting siRNA, 40 nM) from
Dharmacon was used as a transfection control. After 1 day (60%
confluence, D0), the medium was changed and the cells were
incubated with 10 mM MEHP for 4 days. Gene expression was
evaluated as explained above in the section 2.2. Target gene
knockdown was verified by qRT-PCR.
To validate the findings observed by gene silencing we treated
the SW 872 cells with increasing concentrations (of 5, 10, 15 and
50 mM ) of the PKCe translocation inhibitor peptide H-Glu-Ala-
Val-Ser-Leu-Lys-Pro-Thr-OH (EMD4Biosciences, EMD Inc,
Mississauga, ON, Canada) for 4 days. At the end of the
experiments cells were collected and TSPO mRNA levels were
determined by qRT-PCR.
Immunoblot analysis
Cells were incubated in a 10 cm
2 dish for 4 days with 10 mM
MEHP, then collected and lysed in 16 cold RIPA buffer (Cell
Signaling, New England Biolabs Ltd., Pickering, ON, Canada).
Protein extracts were obtained by centrifugation of the homogenate
at 4uC, and the protein concentration was measured using the
Bradford assay (Bio-Rad, Hercules, CA, USA). Proteins (30 mg)
were electrophoretically separated on a 4–20% Tris-glycine SDS
gradient gel (Invitrogen Canada Inc.), then transferred onto
polyvinylidene fluoride membranes (Invitrogen Canada Inc.) and
blocked for 1 h at room temperature in blocking buffer (20 nM
Trizma Base, 100 mM NaCl, 1% Tween-20, 10% skim milk;
Sigma-Aldrich Canada Ltd.). Membranes were then incubated
overnight at 4uC with a rabbit immunoglobulin G (IgG) anti-TSPO
polyclonal antibody(1:300dilution)[33].Toverifytheuniformityof
protein loading, each membrane was also incubated with anti-b-
actin antibody (1:2000 dilution; Cell Signaling). Finally, membranes
werewashedandincubatedfor1 hatroomtemperaturewitha goat
anti-rabbit IgG horseradish peroxidase (1:2000 dilution; Cell
Signaling). The complex was visualized using the Amersham
chemiluminescence kit (GE Healthcare, Baie d’Urfe, QC, Canada),
and a FUJI image reader LAS4000 (FUJIFILM Holdings America
Corporation, Valhalla, NY, USA) for capturing images. The
intensity of each band was measured using Multigauge V3.0
software (FUJIFILM Holdings America Corporation) and normal-
ized to that of the corresponding b-actin band.
[
3H]PK11195 radioligand binding assay
In radioligand binding assays, increasing concentrations of
[
3H]PK11195 (100 ml, 0.39–12.5 nmol/l; specific activity 2.22–
3.33 TBq/mmol; PerkinElmer Inc.) were incubated with mem-
branes containing lysates from control and MEHP treated SW 872
cells (100 ml, 2–10 mg of protein/ml). Briefly, cell pellets were
homogenized in phosphate buffered saline (Invitrogen Canada
Inc.) with a glass Teflon homogenizer (Wheaton Science Products,
Millville, NJ, USA). Protein concentration was determined by the
Bradford method using bovine serum albumin as a standard. The
final volume (300 ml) was obtained by adding 100 ml of water, and
nonspecific binding was measured in the presence of unlabeled
PK11195 (100 ml, 6.6 mmol/l; Sigma-Aldrich Canada Ltd.). The
mixture was incubated at 0–4uC for 90 min. The reaction was
terminated by filtering on glass filters (GF/B; Brandel Inc.,
Gaithersburg, MD, USA) presoaked in 0.5% polyethyleneimine
(Sigma-Aldrich Canada Ltd.) using the Brandel binding apparatus
(Brandel Inc.). The filters were transferred to vials with 3 ml of
Ecolite(+)
TM liquid scintillation cocktail (MP Biomedicals, Solon,
OH, USA) and radioactivity was measured in an LS 5801
RackBeta liquid scintillation counter (Beckman Coulter Inc., Brea,
CA, USA). Scatchard analysis of the saturation isotherms of all
samples was performed using GraphPad (GraphPad Software, La
Jolla, CA) to obtain the maximal number of receptors (Bmax),
expressed as fmol/mg proteins, and dissociation constants (Kd).
Statistical analysis
Data were expressed as mean, S.E.M., and n, and were
analyzed using the Student’s t-test, or one-way ANOVA followed
by Bonferroni’s post hoc test, using the GraphPad Prism program
(GraphPad Software Inc., La Jolla, CA, USA). p,0.05 (*,
#),
p,0.01 (**), and p,0.001 (***) were used as indicators of the level
of significance.
Results
Basal mRNA levels of the differentiation markers PPARs,
TSPO, and PKCe during SW 872 cell differentiation
Since there is little information on SW 872 cell differentiation
markers in literature, we investigated the gene expression of the
MEHP and Adipogenesis
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protein alpha (C/EBP-a), glucose transporter 4 (GLUT4), S100
calcium binding protein B (S100B) [32,34], PPAR-a, PPAR-b/d,
PPAR-c, TSPO, and PKCe, at specific times after differentiation.
At 4, 8, and 12 days after initiation of differentiation in
cultured cells, C/EBP-a mRNA levels increased approximately
5-fold (p,0.01), 7.5-fold (p,0.01), and 12-fold (p,0.001), res-
pectively (Fig. 1A) as previously described [32]. GLUT4 mRNA
levels increased by approximately 3.5-fold (p,0.05) and 3-fold
(p,0.01), 8 and 12 days after initiation of differentiation,
respectively (Fig. 1B), while in those same time periods, S100B
mRNA levels decreased by 73% (p,0.001) and 72% (p,0.001),
respectively (Fig. 1C). At 4, 8, and 12 days after initiation of
differentiation, PPAR-a mRNA levels showed an increase of
approximately 1.5-fold (p,0.05), 2-fold (p,0.01), and 2.6-fold
(p,0.001), respectively (Fig. 1D), while PPAR-b/d mRNA in-
creased by approximately 1.7-fold (p,0.05), 1.6-fold (p,0.05),
a n d2 . 2 - f o l d( p ,0.05), respectively (Fig. 1E). At 4 days after
initiation of differentiation, PPAR-c mRNA levels increased by
approximately 1.5-fold (p,0.01; Fig. 1F), and subsequently,
decreased progressively. This observation is in agreement with
Carmel et al. [32], and suggests an inverse pattern compared to
murine 3T3-L1 preadipocytes [20] where PPAR-c mRNA was
shown to progressively increase.
Because TSPO mRNA was found to be present and to increase
during differentiation in murine preadipocytic 3T3-L1 cells [29],
we also investigated TSPO gene expression during the differenti-
ation of SW 872 cells. We observed an approximate 1.6-fold
increase in TSPO mRNA levels (p,0.05) after 12 days of
differentiation (Fig. 1G), consistent with the increased TSPO
expression observed by Wade et al. during the differentiation of
3T3-L1 mouse preadipocytes [29]. No significant changes were
observed in PKCe transcription during the differentiation of
human SW 872 cells into adipocytes (Fig. 1H).
MEHP increases TSPO mRNA levels
Based on our finding of increased TSPO transcription during
human adipocyte differentiation, we investigated the effect of
MEHP on TSPO gene transcription. While treatment with 1 mM
MEHP produced no effect (Fig. 2B, n=3), treatment with 10 mM
MEHP for 4, 8, and 12 days resulted in approximately 4.5-fold
(p,0.01; n=3), 2.1-fold (p,0.05; n=3), and 1.6-fold (p,0.05;
n=3) increases in TSPO mRNA levels, respectively (Fig. 2A).
Treatment with 50 mM MEHP resulted in an approximately 2-
Figure 1. Basal levels of (A) C/EBP-a, (B) GLUT4, (C) S100B, (D) PPAR-a, (E) PPAR-b/d, (F) PPAR-c, (G) TSPO, (H) PKCe mRNAs
normalized to RPS18. Cells were seeded and collected after the indicated time points; day 0 represents one day after the plating. Results are
expressed in terms of mean and S.E.M., calculated from 3 independent experiments and presented as fold increase or decrease from the value
measured on day 0. Significance (compared to day 0 values) was calculated using one-way ANOVA followed by Bonferroni’s post hoc test; *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0028750.g001
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(p,0.01; n=3; Fig. 2B). Since treatment with 10 mM MEHP for 4
days resulted in the greatest increase in TSPO mRNA expression
levels, this dose and time were chosen for subsequent experiments.
MEHP induces the transcription of PKCe, PPAR-a, and b/d,
and reduces PPAR-c
We have previously reported that PKCe controls TSPO
expression through a MAPK pathway (Raf-1/ERK2) in steroido-
genic cells [27]. We now examined whether MEHP was able to
modify PKCe mRNA levels, as well as PPAR-a, PPAR-b/d, and
PPAR-c in preadipocytes. Treatment with 10 mM MEHP for 4
days induced approximately 1.4-fold and 2.7-fold increases in
PKCe (p,0.01; n=3; Fig. 2B) and PPAR-a (p,0.01; n=3;
Fig. 2C) mRNA levels, respectively. On the other hand, PPAR c
mRNA levels decreased 36% (p,0.001; n=3; Fig. 2C), and
PPAR b/d transcription was not significantly modified (Fig. 2C) by
MEHP, compared to control (n=3).
PMA increases TSPO mRNA levels
We tested the effect of the PKCe agonist PMA on TSPO
mRNA levels in SW 872 cells. Treatment with 10, 50,
and 100 nM PMA for 4 days increased TSPO mRNA levels
by approximately 1.8-fold, 1.6-fold, and 1.5-fold, respectively,
compared to control (p,0.01, p,0.01 and p,0.05; n=3;
Fig. 2D).
MEHP induces the transcription of differentiation markers
To examine the effect of MEHP on SW 872 differentiation, we
determined the mRNA levels of the following well-known
differentiation markers: acetyl-CoA carboxylase alpha (ACACA)
and adenosine triphosphate citrate lyase (ACLY), which are
involved in the lipogenesis pathway, GLUT1 and GLUT4, which
are involved in glucose transport, and S100B, a free fatty acid
carrier that is highly expressed in the early stage of differentiation
[34,35,36]. The effect of MEHP on C/EBP-a levels was not
assessed, as C/EBP-a is expressed at high levels in terminally
differentiated cells [37], while the effect of MEHP on TSPO is
predominantly in the early phase of SW 872 cell differentiation.
Treatment with 10 mM MEHP for 4 days caused increases in the
mRNA levels of these differentiation markers, compared to
control, as follows: ACACA, approximately 2.8-fold; ACLY,
approximately 2.6-fold; GLUT1, approximately 1.7-fold; GLUT4,
2.4-fold; S100B, approximately 1.8-fold (p,0.05; n=3; Fig. 3A).
MEHP exposure inhibits BrdU incorporation
Since proliferation and differentiation have an inverse relation-
ship during adipocyte differentiation [38], we assessed the effect of
MEHP on SW 872 cell proliferation using the BrdU assay. We
Figure 2. Effect of MEHP and PMA on the gene transcription of TSPO, PKCe, PPAR-a, PPAr-b/d, and PPAR-c. (A) Dose response of TSPO
gene expression after 4, 8 and 12 days of treatment with 1, 10, and 50 mM MEHP. (B) Effect of 10 mM MEHP on PKCe gene expression after 4 days of
treatment. (C) Effect of 10 mM MEHP on PPAR-a, PPAR-b/d, and PPAR-c gene expression after 4 days of treatment. (D) Effect of 10, 50, or 100 10 nM
PMA on TSPO gene expression after 4 days of treatment. Cells were seeded for 24 h before treatment with MEHP (A–C) or PMA (D) and collected after
the indicated time points (A) or after 4 days (B–D). qRT-PCR results are normalized to RPS18, expressed in terms of mean and S.E.M. calculated from 3
independent experiments, and presented as fold increase or decrease compared to control. One-way ANOVA followed by Bonferroni’s post hoc test
(A) or Student’s t-test (B–D) was used to calculate statistical significance; *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0028750.g002
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SW 872 preadipocytes upon MEHP treatment, compared to
control cells (Fig. 3B), indicating that the compound has an
inhibitory effect on cell proliferation.
MEHP has no effect on triglyceride content
Preadipocytes have a fibroblast-like morphology, but become
spherical and filled with lipid droplets upon differentiation into
adipocytes. Four days after seeding, SW 872 cells still exhibit the
morphological characteristics of preadipocytes, and are poor in
lipid content [39,40]. We quantified the triglyceride content of SW
872 cells after treatment with MEHP for 4 days, and at 6 days to
exclude a possible delayed effect on the triglyceride production
machinery following MEHP administration. The results obtained
showed no change in cellular triglyceride content after treatment
with MEHP, compared to control cells (Fig. 3C).
MEHP regulates TSPO mRNA levels acting through
PPAR-a and PPAR-b/d
We have previously shown that the effect of MEHP on TSPO
mRNA levels was mediated through the action of PPAR-a in MA-
10 Leydig cells [24]. We therefore investigated the role of PPARs
in mediating the effect of MEHP on TSPO transcription in SW
872 cells. PPAR-a, b/d and c were silenced using specific siRNAs,
and the levels of TSPO mRNA were determined following
treatment with 10 mM MEHP for 4 days.
We initially verified the knockdown of PPAR gene expression by
the various siRNAs, and observed, on average, a 40–80%
reduction in PPAR mRNA levels, as shown in Fig. 4A. TSPO
mRNA levels were reduced by 75% in samples transfected with
PPAR-a siRNA and treated with MEHP, compared to cells
transfected with scrambled siRNA and treated with MEHP
(p,0.05; Fig. 4B). We observed a similar reduction in TSPO
mRNA levels in cells transfected with PPAR-b/d siRNA and
treated with MEHP (p,0.05; Fig. 4B), while no change was
observed in TSPO mRNA levels in cells transfected with PPAR-c
or PKCe siRNAs and treated with MEHP (Fig. 4B). These
observations suggest that the effect of MEHP on TSPO gene
transcription is mediated by PPAR-a and b/d.
MEHP acts on PKCe gene transcription through PPAR-a
We demonstrated earlier that PKCe mRNA levels increased
upon treatment with MEHP (Fig. 2B). We examined whether the
PPARs were mediating this effect. Among the PPARs tested,
silencing of PPAR-a alone resulted in a reduction of PKCe mRNA
by 50% (p,0.05) after treatment with MEHP, compared to
control cells transfected with scrambled siRNA and treated with
MEHP (Fig. 4C).
MEHP reduces TSPO protein expression
Changes in TSPO protein levels were examined by immunoblot
analyses and the [
3H]PK 11195 ligand binding assay. Immunoblot
analysis of SW 872 cell lysates at D0 showed the presence of the
TSPO dimer at 36 kDa [41,42]. A significant increase in TSPO
levels (p,0.05) was observed in untreated cells after 4 days of
differentiation (Fig. 5A), and this differentiation-induced increase
in TSPO protein levels was inhibited by treatment with MEHP
treatment (Fig. 5A). Radioligand binding studies followed by
Scatchard analysis of the saturation isotherms confirmed these
results, showing a significant reduction in the maximal number of
binding sites (Bmax) in MEHP treated cells (93.961.4 fmol/mg
protein), compared to control cells (114.261.0 fmol/mg protein;
p,0.05; Fig. 5B); however, no significant changes in the affinity
(Kd) of TSPO for the ligand were observed.
TSPO knockdown increases the levels differentiation
markers
Based on our observation of TSPO downregulation upon
MEHP treatment during differentiation, we examined the effect of
TSPO knockdown on mRNA levels of PPAR-c and other
differentiation markers. Silencing of TSPO expression using
TSPO siRNA was highly effective (,87%; Fig. 6A). After 4 days
in culture, silencing of TSPO resulted in 34% reduction in PPAR-
c mRNA levels (p,0.001), while the mRNA levels of S100B,
ACACA, and ACLY showed increases of approximately 2.3-fold
(p,0.01), approximately 1.9-fold (p,0.05), and approximately
1.9-fold (p,0.05), respectively, compared to control (Fig. 6B).
Discussion
The impact of plasticizers on human health is one of the main
issues in the modern era, due to their extensive use in the industrial
production. Although initially regarded as exhibiting low toxicity
[43,44], phthalates were later shown to be carcinogenic [45,46]
and teratogenic [47], to affect fertility and litter size [47–49], and
to exert adverse effects on the reproductive system [1]. Indeed, we
Figure 3. MEHP induces the differentiation of SW 872 cells. (A)
qRT-PCR products of ACACA, ACLY, GLUT1, GLUT4 and S100B mRNA
normalized to RPS18 and presented as fold increase or decrease
compared to control, 4 days after treatment with 10 mM MEHP. (B)
Proliferation assay. Cells were seeded for 24 h before treatment with
10 mM MEHP and the assay was performed as described in section 2.4
(C) Cellular triglyceride content assay. Cells were seeded for 24 h before
treatment with 10 mM MEHP and collected after 4 or 6 days to assay
triglyceride content. D0, D4CTRL, and D4M10 represent untreated cells
at day 0, untreated cells at day 4, and MEHP-treated cells at day 4,
respectively. Results are expressed in terms of mean and S.E.M.,
calculated from three independent experiments. Student’s t-test was
used to calculate statistical significance compared to control; *p,0.05.
doi:10.1371/journal.pone.0028750.g003
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effects on testosterone production in the rat [50], and that MEHP
acts as a mitochondrial toxicant and lipid metabolism disruptor in
Leydig cells [51]. The purpose of the present work was to evaluate
the effect of MEHP on the differentiation of human SW 872
preadipocytes, and to determine the involvement of TSPO and the
PPAR signaling pathway in this process.
It was previously demonstrated that MEHP directly activates
PPAR-c and promotes adipogenesis in murine 3T3-L1 cells [52].
After 4 days of treatment with 10 mM MEHP, we observed an
increase in the mRNA levels of the early differentiation markers
ACACA and ACLY, key enzymes for de novo lipogenesis, as well
as in the mRNA levels of GLUT1, GLUT4, and S100B. This
effect on gene expression coincided with a reduction in cellular
proliferation; however, the cellular triglyceride content was not
modified. The absence of any change in the triglyceride content is
likely due to the well-documented poor lipid content of this cell
line [39], especially in the early phase of differentiation [40].
Nevertheless, these data taken together indicate that MEHP exerts
a differentiating effect in human preadipocytes in agreement with
the results obtained with 3T3-L1 mouse preadipocytes [52].
Treatment with 10 mM MEHP for 4 days significantly increased
the transcription of TSPO mRNA, with the maximal increase
observed at 4 days, and a progressive decline thereafter. This
suggests that the effect of MEHP is transient, with a maximal effect
at or around day 4. We have previously demonstrated that PKCe
affects TSPO expression through the MAPK pathway (Raf-1/
ERK2) in steroidogenic cells [27]. In the current study, we found
that TSPO mRNA increased in SW 872 cells after 4 days of
treatment with PMA, a PKCe agonist. However, gene silencing of
PKCe followed by treatment with MEHP did not produce a
significant decrease in TSPO mRNA expression, indicating that
the transcriptional effect of MEHP is PKCe–independent in SW
872 cells. Moreover, data obtained by using a PKCe translocation
inhibitor peptide at different concentrations, also confirmed that
PKCe has no role in mediating the MEHP-induced TSPO mRNA
increased expression in SW 872 cells (data not shown). On the
contrary, further gene silencing studies demonstrated that the
transcriptional effect of MEHP on TSPO is mediated by PPAR-a
and PPAR-b/d. The relationship between the PKC family and the
PPARs is not yet clear, although peroxisome proliferators have
been shown to stimulate the activity of protein kinase C in vitro
[53]. In this study, we have demonstrated that the PPAR agonist
MEHP directly affects the transcription of PKCe mRNA, and that
knocking down PPAR-a can block this effect. It is known that
PPAR ligands regulate the transcription of their own receptors; for
Figure 4. The effect of MEHP on TSPO gene expression is mediated by PPAR-a and PPAR-b/d , and on PKCe gene expression by
PPAR-a. (A) PPAR-a, PPAR-b/d, PPAR-c and PKC mRNA levels are greatly reduced following treatment with gene-specific siRNAs compared to
treatment with scrambled siRNA. (B) Effect of gene-specific siRNA treatment on TSPO transcription, with or without (+/2) MEHP, compared to similar
treatment with scrambled siRNA (SCR). (C) Effect of gene-specific siRNA treatment on PKCe transcription, with or without (+/2) MEHP compared to
similar treatment with scrambled siRNA (SCR). Cells were seeded for 24 h before treatment with MEHP, and then transfected with siRNA specific to
PPAR-a, PPAR-b/d, PPAR-c, and PKCe knockdown. Cell lysates were collected after 4 days. qRT-PCR results are expressed in terms of mean and S.E.M.,
calculated from three independent experiments. Student’s t-test was used to calculate statistical significance compared to scrambled siRNA control in
the absence (*) or presence (#) of MEHP; *p,0.05, **p,0.01, ***p,0.001,
#p,0.05.
doi:10.1371/journal.pone.0028750.g004
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a mRNA [54,55], while PPAR-c agonists downregulate PPAR-c
mRNA [56,57]. We observed an increase in PPAR-a mRNA and
a decrease in PPAR-c mRNA following MEHP treatment. In light
of the decrease in PPAR-c mRNA levels observed in SW 872 cells
during differentiation [32], our observed reduction in PPAR-c
mRNA is further proof of MEHP-induced differentiation.
Using an immunoblot assay, we observed a decrease in TSPO
protein expression following MEHP treatment. To confirm this
observation, we also carried out a saturation binding assay for
TSPO using the radiolabeled ligand PK 11195. Scatchard analysis
of the saturation isotherms confirmed a significant decrease in the
number of PK 11195 ligand binding sites in MEHP-treated cells,
compared to the number in control cells. Although the changes
observed in TSPO levels range from 20–35% one should consider
that TSPO is a mitochondrial protein thought by many as a
housekeeping gene. In mitochondria, TSPO comprises 2% of the
OMM protein and is part of the mitochondrial transition pore
[25,26]. As noted earlier TSPO has been implicated in
mitochondrial respiration, lipid import, protein import, biogenesis
and apoptosis [25,26]. Moreover, mitochondrial function has been
closely linked to adipocyte differentiation and homeostasis [58].
Thus, even small changes in TSPO expression could have a major
impact on adipogenesis.
To follow up on these observations, we analyzed the effect of
siRNA silencing of the TSPO gene on the mRNA levels of the
differentiation markers. Interestingly, the silencing of TSPO results
in an increase the levels of differentiation markers of the enzymes
Figure 5. MEHP treatment results in decreased TSPO protein level. (A) Densitometric analysis of TSPO immunoblot. Cells were seeded for
24 h before treatment with 10 mM MEHP and collected at day 0 and after 4 days. D0, D4C, and D4M10 represent untreated cells at day 0, untreated
cells at day 4, and MEHP-treated cells at day 4, respectively. (B) Saturation binding assay. Cells were seeded for 24 h before treatment with MEHP and
collected after 4 days. D4C, and D4M10 represent untreated cells and MEHP-treated cells at day 4, respectively. Results are expressed in terms of
mean and S.E.M., calculated from two independent experiments. Student’s t-test was used to calculate statistical significance compared to control
(*p,0.05), or to day 0 (
#p,0.05).
doi:10.1371/journal.pone.0028750.g005
Figure 6. TSPO gene knockdown decreases PPAR-c transcription and increases transcription of S100B, ACACA, and ACLY. (A) TSPO
mRNA levels following treatment with gene-specific siRNA, compared to similar treatment with scrambled siRNA. (B) Effect of gene-specific siRNA
treatment on PPAR-c, S100B, ACACA, and ACLY mRNA levels compared to treatment with scrambled siRNA. Cells were transfected with siRNA as
described in section 2.5, and collected after 4 days. qRT-PCR results are expressed in terms of mean and S.E.M., calculated from three independent
experiments. Student’s t-test was used to calculate statistical significance compared to scrambled siRNA treatment; * p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0028750.g006
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storage. It has been previously shown that TSPO mRNA
expression increases during the differentiation of mouse preadi-
pocytes, and decreases when the process is completed [29]. In this
study, we observe that MEHP treatment results in an increase in
TSPO mRNA levels; however, this increase is not maintained
during differentiation, and a progressive reduction of the protein
levels is seen, as in mature adipose tissue.
In conclusion, our observations taken together indicate that
MEHP acts as a differentiating agent in human adipocytes,
specifically in the early phase of the differentiation process, where
SW 872 cells seem to be more sensitive to the endocrine disruptor
(Fig. 7). Our data also suggest that TSPO could be considered an
important player in the differentiation process, whose presence is
essential for adipocyte development. To our knowledge, this is a
newly identified function of TSPO in cell differentiation and in the
maintenance of the balance between lipid trafficking and
metabolism. Further studies are needed to fully characterize the
relationship between PPAR-c and TSPO, in the light of the
observation that PPAR-c mRNA transcription is affected by
knocking down TSPO.
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